# GSK filing accepted by EMA for Bexsero booster label update

- Link: https://www.directorstalkinterviews.com/gsk-plc-gsk-filing-accepted-by-ema-for-bexsero-booster-label-update/4121256709
- Published: 2026-07-20T07:15:38+01:00
- Author: Ethan Davis

**[Gsk Plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
[LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
has announced the European Medicines Agency (EMA) has accepted a submission to update
the label for **Bexsero** to include a single-dose booster for individuals aged 
10 years and older who were previously vaccinated with **Bexsero**.

If a one-dose booster is approved, those vaccinated with **Bexsero** in childhood
could receive a single **Bexsero** dose at age 10 years or older. If adopted, a 
booster could help reduce the overall burden of invasive meningococcal disease (
IMD) in countries with established infant MenB programmes.

IMD is an uncommon but severe illness caused by _Neisseria meningitidis_. While 
the highest incidence is in infants and young children, there is also a peak in 
15-24 year olds^(1,2), often linked to behaviours that increase transmission, such
as close contact through kissing, sharing drinks, and living in shared accommodation
^(3).

The submission is supported by a Phase 3b, open-label, multi-centre study that evaluated
the immune response of a **Bexsero** booster dose in individuals 10 to 20 years 
old who received the complete primary series during infancy. The data show a single
dose was effective in boosting the immune responses of individuals vaccinated as
infants. Full data will be presented at the 25th International Pathogenic Neisseria
Conference (IPNC) in September.

### About invasive meningococcal disease (IMD)

Invasive meningococcal disease (IMD) is a rare, life-threatening disease caused 
by _Neisseria meningitidis_ that can progress rapidly and has a fatality rate of
4-20%^(4). Up to 20% of IMD survivors have severe, life-changing sequelae, and the
physical and psychological consequences of IMD can substantially impact quality 
of life^(5). In 2024 in the European Union/European Economic Area, 56% of confirmed
cases of IMD were due to serogroup B in all age groups under 65 years. The notification
rate for IMD was highest among young children less than 1 year old (6.3 cases per
100 000), followed by children aged 1-4 years (1.38 confirmed cases per 100 000)
and third highest in adolescents and young adults aged 15-24 years (0.83 per 100
000)^(1).

### About **Bexsero** (4CMenB)

**Bexsero** is registered in 61 countries for the prevention of Invasive Meningococcal
Disease (IMD) caused by _Neisseria meningitidis_ serogroup B. In Europe, it is included
in 15 national and/or regional immunisation programmes for infants, and 3 national
immunisation programmes for adolescents. Around 138 million doses of Bexsero have
been distributed globally since 2015^(6).

### About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and
talent to get ahead of disease together. Find out more at www.gsk.com.

GSK cautions investors that any forward-looking statements or projections made by
GSK, including those made in this announcement, are subject to risks and uncertainties
that may cause actual results to differ materially from those projected. Such factors
include, but are not limited to, those described in the “Risk Factors” section in
GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q1 Results for 2026.

### References

1. European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal
disease: Annual Epidemiological Report for 2024 Available at: https://www.ecdc.europa.
eu/sites/default/files/documents/invasive-meningococcal-disease-annual-epidemiological-
report-2024.pdf. Last accessed: June 2026

2. UKHSA 2013, Meningococcal: the green book, chapter 22. Available at: <https://
assets.publishing.service.gov.uk/media/6849adb83a2aa5ba84d1df71/Meningococcal-green_book_chapter-
22-10-6-25.pdf> Last accessed: June 2026

3. Burman C, Serra L, Nuttens C, et al. Meningococcal disease in adolescents and
young adults: a review of the rationale for prevention through vaccination. Human
Vaccines & Immunotherapeutics. 2019 ;15(2):459-469. <https://doi.org/10.1080/21645515.2018.1528831
>

### 4. Wang B et al. Vaccine 2019;37:2768-2782.

5. Centers for Disease Control and Prevention. https://www.cdc.gov/pinkbook/hcp/
table-of-contents/chapter-14-meningococcal-disease.html. Last accessed June 2026.

### 6. GSK Data on file, REF-310855. 138 million doses shipped from 2015 to October 2025.

Share on:
